All In Biotech

Drug Trial Radar · NCT04569747

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

20-347 NCT Number Title A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT)

Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

393

Actual

Start

Jan 11, 2021

Primary completion

Mar 23, 2029

Study completion Sep 1, 2032

Sponsor

Lead sponsor
Dana-Farber Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Genentech, Inc.
First posted
Sep 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research study is studying a combination of HER2-directed therapies (trastuzumab and pertuzumab) and hormonal therapy as a treatment after surgery for hormone receptor positive breast cancer. The study drugs involved in this study are: * A combination of trastuzumab and pertuzumab given as an injection under the skin (PHESGO) * Hormonal (endocrine) Treatment

Conditions

  • HER2-positive Breast Cancer
  • Invasive Carcinoma of the Breast
  • Breast Cancer
  • Node Negative Breast Cancer
  • Micrometastasis Breast Cancer
  • Hormone Receptor Positive Breast Cancer

Interventions

  • Pertuzumab+TRASTUZUMABCombination product

    Trastuzumab + pertuzumab SC FDC (PHESGO) will be administered on Day 1 of each 21-day cycle , subcutaneous, fixed dose

  • ADJUVANT ENDOCRINE THERAPYDrug

    Oral, daily per cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive Disease Free Survival at 3 YearsTime frame: 3 Years

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • Stamford Hospital

    Stamford, Connecticut

  • University of Miami- Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Winship Cancer Institute at Emory University Hospital Midtown

    Atlanta, Georgia

  • Emory University - Winship Cancer Institute

    Atlanta, Georgia

  • Winship Cancer Institute at Emory Saint Joseph's Hospital

    Atlanta, Georgia

  • University of Chicago Medical Center

    Chicago, Illinois

  • Indiana University Health Schwarz Cancer Center

    Indianapolis, Indiana

  • Indiana University Health - Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana

  • Indiana University Sidney and Lois Eskenazi Hospital

    Indianapolis, Indiana

  • Eastern Maine Medical Center (Northern Light)

    Brewer, Maine

  • Dana Farber Cancer Institite

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana-Farber Brigham Cancer Center - Foxborough

    Foxborough, Massachusetts

  • Cape Cod Healthcare Center

    Hyannis, Massachusetts

  • Dana-Farber at Milford

    Milford, Massachusetts

  • Dana-Farber at South Shore Hospital

    Weymouth, Massachusetts

  • Dana-Farber Cancer Insitute at Londonderry Hospital

    Londonderry, New Hampshire

  • New York University Langone Hospital -Brooklyn

    Brooklyn, New York

  • New York University Langone Hospital - Long Island

    Mineola, New York

  • New York University Langone Health

    New York, New York

  • UNC Rex Hematology Oncology Associated - Cary

    Cary, North Carolina

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • UNC Rex Hematology Oncology Associates of Garner

    Garner, North Carolina

  • UNC Rex Cancer Center

    Raleigh, North Carolina

  • UNC Rex Cancer Center at Wakefield

    Raleigh, North Carolina

  • The Christ Hospital

    Cincinnati, Ohio

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • Greco-Hainsworth Centers for Research/Tennessee Oncology

    Nashville, Tennessee

  • SCRI Oncology Partners

    Nashville, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Baylor College of Medicine Medical Center

    Houston, Texas

  • MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.